Collins F M
Antimicrob Agents Chemother. 1975 Apr;7(4):453-6. doi: 10.1128/AAC.7.4.453.
Treatment of specific-pathogen-free CD-1 mice with oral doses of 10 or 100 mg of niridazole per kg of body weight given 24 h before challenge and then every other day for up to 15 days altered the growth curves for Listeria monocytogenes, Mycobacterium bovis (BCG Montreal), M. tuberculosis H37Rv, and Salmonella enteritidis seen in the livers and spleens of the treated animals. Niridazole in an oral dosage of 10 mg/kg reduced (but did not eliminate) tuberculin hypersensitivity in the mycobacteria-infected mice. Both delayed hypersensitivity and antimycobacterial resistance quickly returned to normal levels once the drug treatment was stopped. Niridazole treatment reduced the growth of S. enteritidis in both intravenously and intragastrically challenged mice; this seemed to be due to the antibacterial action of the drug on the salmonellae both in vitro and in vivo.
在攻击前24小时给无特定病原体的CD - 1小鼠口服每千克体重10或100毫克硝唑咪，然后每隔一天给药，持续长达15天，这改变了在接受治疗动物的肝脏和脾脏中观察到的单核细胞增生李斯特菌、牛分枝杆菌（蒙特利尔卡介苗）、结核分枝杆菌H37Rv和肠炎沙门氏菌的生长曲线。口服剂量为10毫克/千克的硝唑咪降低了（但未消除）分枝杆菌感染小鼠的结核菌素超敏反应。一旦停止药物治疗，迟发型超敏反应和抗分枝杆菌抗性都迅速恢复到正常水平。硝唑咪治疗减少了静脉内和胃内攻击小鼠中肠炎沙门氏菌的生长；这似乎是由于该药物在体外和体内对沙门氏菌的抗菌作用。
